[Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].

CONCLUSIONS: Immuno-oncologic treatment using CPIs has become an integral part of the management of patients with advanced bladder cancer. For biomarker-based patient selection and combination therapies, there is an urgent need for further investigations within clinical trial protocols. PMID: 32468092 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32468092?dopt=Abstract

Source: Der Urologe. Ausg. A - May 27, 2020 Category: Urology & Nephrology Authors: Todenhöfer T, Boegemann M Tags: Urologe A Source Type: research